Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review
The literature on Thymosin Beta-4 and TB-500 shows significant interest but is largely preclinical, with limited human evidence for musculoskeletal applications.
Where it sits
this study against the rest of the tb-500 (thymosin beta-4 fragment) corpusSummary and findings
This scoping review evaluated the literature on Thymosin Beta-4 (TB4) and TB-500 in the context of tissue healing and musculoskeletal repair. A total of 80 studies were included, with a focus on mixed and in vitro designs, and limited human evidence specifically related to TB-500. The findings suggest a disparity in the available research, particularly in direct musculoskeletal applications.
Abstract
Thymosin beta-4 (TB4) and the related compound commonly referred to as TB-500 are widely discussed in tissue healing and musculoskeletal medicine, but the scope and nature of the supporting literature remain unclear. We conducted a scoping review to map the evidence on TB4 and TB-500 in tissue healing, regeneration, and musculoskeletal repair. PubMed, Europe PMC, and ClinicalTrials.gov were searched through March 2026. English-language in vitro, animal, human, and registered clinical trial sources directly evaluating TB4, TB-500, or included derivatives in repair-related contexts were eligible. Of 1772 records identified, 80 studies were included. The evidence base was weighted toward mixed and in vitro designs, and most studies evaluated TB4 rather than TB-500. The most common tissue categories were wound/skin/soft tissue, vascular/endothelial, ocular/cornea, and bone. Direct musculoskeletal tissue categories such as tendon, ligament, muscle, cartilage, and spine/intervertebral disc were comparatively sparse. Human evidence was concentrated in ocular/cornea and wound/skin/soft tissue settings, whereas direct TB-500 evidence was limited to a single included study. Overall, the mapped literature supports the popular interest in several repair-related pathways but remains unevenly distributed and largely preclinical, with limited human evidence directly relevant to musculoskeletal applications.
Background
This paper addresses the biological role of Thymosin Beta-4 (TB-500) in tissue healing and musculoskeletal repair, an area of interest due to the peptide's potential regenerative properties. Prior research has indicated that TB-500 may influence cell migration and tissue repair processes. Understanding the implications of TB-500 in clinical settings is crucial for practitioners considering its use in regenerative medicine.
Methods
The review compiles and analyzes data from various studies related to TB-500, focusing on its effects on tissue healing and regeneration. Specific details regarding the study designs, populations, doses, or durations were not reported in the abstract. The review aims to summarize existing literature rather than present new experimental findings.
Results
Not reported in abstract.
Interpretation
The findings of this review are intended to provide a comprehensive overview of TB-500's potential applications in healing and regeneration. However, without specific numeric findings or effect sizes, it is challenging to assess the clinical significance of the reported data. The lack of detailed outcomes limits the applicability of the review's conclusions for clinical practice.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.
- No specific outcomes or numeric data provided.
- Review format limits the ability to draw definitive conclusions.
- Lack of detailed methodology from included studies.